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Improving MELD for use in acute liver failure
To the Editor:
Bechmann et al. [1] presented an interesting modiﬁcation to the
Model for End-Stage Liver Disease (MELD) score using M-65, a
marker of hepatic necrosis, as a substitute for bilirubin in the
MELD equation which they subsequently applied to a series of
patients with acute liver failure (ALF). The statistical justiﬁcation
and reporting of the subsequent results is useful to discuss.
MELD is constructed (Eq. (1)) from serum creatinine, bilirubin,
and internationalized normalized ratio (INR), and is a highly suc-
cessful risk stratiﬁcation marker for death in patients with cirrho-
sis. While it is used for prognostication in ALF in the USA, there is
considerable doubt as to its applicability in this setting partly
because of the lack of utility of bilirubin as an early marker of dis-
ease severity in ALF. MELD was constructed [2] from a Cox-
proportional regression analysis of 231 patients with cirrhosis at
the time of transjugular intrahepatic portosystemic shunt (TIPSS),
where the quantitative predictors were logarithmically trans-
formed to reduce the effect of inﬂuential outliers. The coefﬁcients
seen in the MELD equation are the regression coefﬁcients derived
from the computation using these transformed predictors.
½MELD score ¼ 9:57 LnðCreatinineÞ þ 3:78 LnðBilirubinÞ
þ 11:2 LnðINRÞ þ 6:43 ð1Þ
Creatinine – mg/L, Bilirubin – mg/dL, INR – unitless.
Bechmann et al.’s implantation of M-65 into MELD in this ALF
cohort is concerning for a number of reasons. Their analysis is
based on outcome alone and not the length of survival and there-
fore uses logistic regression (via Receiver Operating Characteris-
tic (ROC) curves) not proportional hazards. In any multivariate
analysis, the independence of predictors must be assessed and
M-65, while having a clear univariate correlation with outcome,
was not tested against INR and creatinine in a logistic or propor-
tional hazards multivariate model. Furthermore, the effect of INR
and creatinine on survival in ALF is likely to be different from cir-
rhosis; in fact, de novo regression modeling may give different
regression coefﬁcients that lead to a more useful MELD improve-
ment rather than the assumption that the regression coefﬁcients
from patients with a different disease in a different country are
immediately transferable.
Improvements in modeling when assessed by ROC curve anal-
ysis can be assessed quantitatively as was lacking in the Bechman
et al. analysis. ROC curve comparisons via the Delong method [3]
are non-parametric, well validated, and produce a p value for the
comparison. While sensitivity and speciﬁcity improvements were
discussed (again without quantitative comparators) and ROC
curves were produced, there was no head to head graphical or
quantitative ROC curve comparison between MELD and its mod-
iﬁcation or comparison among new multivariate models. These
would have strengthened the analysis.
Statistical models are not necessarily interchangeable
between diseases or populations, and repeat modeling is neces-
sary to provide evidence of validity of the model. Statistical
assessment of improvements of multivariate models is available
and should be reported to allow the quantitation of the signiﬁ-
cance of any improvement.
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Letters to the EditorReply to the Letter to the Editor ‘Improving MELD for use in acute
liver failure’This is a reply to the Letter to the Editor by Dr. McPhail:
The authors thank Dr. McPhail for initiating this valuable dis-
cussion on our manuscript. We agree with Dr. McPhail that the
MELD score was initially developed to stratify the risk of deathJournal of Hepatologyin a cohort of patients with end-stage chronic liver disease to
predict death after a TIPS procedure, as we pointed out in the
introduction of the original manuscript [1,2]. We thus agree with
Dr. McPhail that the MELD score was neither primarily designed2011 vol. 54 j 1320–1326
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Fig. 1. Head-to-head comparison of ROC curves for MELD vs. modiﬁed MELD
on admission. We found a better prognostic value of the modiﬁed MELD
(MMELD, straight line) compared to the MELD score (dotted line) in patients
admitted for ALF (n = 68). When we computed MMELD and MELD head to head,
the AUC of the ROC curve was higher in MMELD.
JOURNAL OF HEPATOLOGYas an allocation tool for patients with end-stage liver disease, nor
as a tool to predict outcome in acute liver failure (ALF). However,
to date, the MELD score in its current form, without adaptation of
the original regression coefﬁcients used in the original Mayo
model, is widely used to allocate grafts for patients with end-
stage liver disease; it was found to predict survival and thus
the need for transplantation better than the previously used
waiting list and Child-Pugh classiﬁcation [3]. In particular, the
low frequency of viral liver diseases in the original Mayo cohort
is contradictory to current observations that the number of trans-
plantations due to HCV cirrhosis is dramatically rising. Thus, it is
questionable whether the original regression calculations reﬂect
the overall patient population with end-stage liver diseases of
the present date. However, UNOS and Eurotransplant make use
of the original formula and the current MELD formula is consid-
ered the gold standard in organ allocation, worldwide.
Furthermore, several recent publications used the original
Mayo formula to predict survival in ALF and found the MELD to
be superior to previous calculations (i.e. KCC) [4,5]. We observed
that (i) bilirubin values are of no predictive value within the
MELD calculation regarding survival of ALF patients and that
(ii) the circulating CK18 as assessed by M65 ELISA is of good
prognostic value in this cohort. (iii) When we replaced bilirubin
with M65 in the original formula, we found a dramatic improve-
ment of predictive value in our cohort of ALF patients (Fig. 1). The
aim of our study was to identify tools to predict if a particular
patient needs a transplant, or if her/his liver has the capacity toPropofol in patients with
hepatic encep
To the Editor:
We read with interest the article by Khamaysi et al. [1] in
which it was concluded that sedation with propofol does not
Journal of Hepatology 201regenerate spontaneously, a situation which rarely occurs in
chronic liver disease. Therefore, we chose the outcome as an end-
point rather than time to death or transplantation.
We agree with Dr. McPhail that ideally, the development of a
multivariate regression model would improve the quality of the
modiﬁed MELD as well as the original MELD calculations. How-
ever, the available sample size was underpowered for this type
of statistical method; for this reason, we decided to perform these
analyses after a validation period with a larger patient cohort in a
currently initiated prospective study. This is especially important
since we might identify even better predictors, depending on the
different etiologies of ALF in a larger cohort.
At the end, we agree that statistical models are not directly
interchangeable between different diseases and populations, thus
repeated modelling is necessary to improve the validity of a
model, which was also suggested by D. Samuel [6]. We continue
to include data from more patients in order to validate our model
and perform multivariate regression analysis. Due to the fortu-
nately rare disease, a registry of ALF-patients in Europe would
enhance the available patient numbers and thus help to further
improve our understanding and management of these patients.
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exacerbate subclinical hepatic encephalopathy (SHE), and allows
a shorter recovery time and a shorter time to discharge than
midazolam.
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